



# FEP Medical Policy Manual

## FEP 1.01.24 Interferential Current Stimulation

**Effective Policy Date: October 1, 2023**

**Original Policy Date: September 2011**

### **Related Policies:**

1.01.09 - Transcutaneous Electrical Nerve Stimulation

7.01.29 - Percutaneous Electrical Nerve Stimulation and Percutaneous Neuromodulation Therapy

## Interferential Current Stimulation

### Description

### Description

Interferential current stimulation (IFS) is a type of electrical stimulation used to reduce pain. The technique has been proposed to decrease pain and increase function in individuals with osteoarthritis and to treat other conditions such as constipation, irritable bowel syndrome, dyspepsia, and spasticity.

Interferential current stimulation (IFS) is a type of electrical stimulation that has been investigated as a technique to reduce pain, improve function and range of motion, and treat gastrointestinal disorders.

IFS uses paired electrodes of 2 independent circuits carrying high-frequency and medium-frequency alternating currents. The superficial electrodes are aligned on the skin around the affected area. It is believed that IFS permeates tissues more effectively, with less unwanted stimulation of cutaneous nerves, and is more comfortable than transcutaneous electrical nerve stimulation. There are no standardized protocols for the use of IFS; IFS may vary by the frequency of stimulation, the pulse duration, treatment time, and electrode-placement technique.

### OBJECTIVE

The objective of this evidence review is to determine whether interferential current stimulation improves the net health outcome in individuals with musculoskeletal conditions, gastrointestinal disorders, or post-stroke spasticity.

## POLICY STATEMENT

Interferential current stimulation is considered **investigational**.

## POLICY GUIDELINES

None

## BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

## FDA REGULATORY STATUS

A number of IFS devices have been cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process, including the Medstar™ 100 (MedNet Services) and the RS-4i (RS Medical). Interferential current stimulation may be included in multimodal electrotherapy devices such as transcutaneous electrical nerve stimulation and functional electrostimulation.

## RATIONALE

### Summary of Evidence

For individuals who have musculoskeletal conditions who receive interferential current stimulation (IFS), the evidence includes randomized controlled trials (RCTs) and meta-analyses. Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. Placebo-controlled randomized trial(s) have found that IFS when used to treat musculoskeletal pain and impaired function(s), does not significantly improve outcomes. Meta-analyses for IFS in musculoskeletal conditions have generally found IFS to be no more effective than other therapies. One network meta-analysis did find improvement with IFS compared with control, but the analysis is limited by indirect comparisons. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have gastrointestinal disorders who receive IFS, the evidence includes RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. Interferential current stimulation has been tested for a variety of gastrointestinal conditions, with a small number of trials completed for each condition. The results of the trials are mixed, with some reporting benefit and others not. This body of evidence is inconclusive on whether IFS is an efficacious treatment for gastrointestinal conditions. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have poststroke spasticity who receive IFS, the evidence includes RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The RCTs had small sample sizes and very short follow-up (immediately posttreatment to 5 weeks). The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## SUPPLEMENTAL INFORMATION

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

## American College of Occupational and Environmental Medicine

The American College of Occupational and Environmental Medicine published several relevant guidelines. For shoulder disorders, guidelines found the evidence on interferential current stimulation (IFS) to be insufficient and, depending on the specific disorder, either did not recommend IFS or were neutral on whether to recommend it.<sup>15</sup> For low back disorders, guidelines found the evidence on IFS to be insufficient and did not recommend it.<sup>16</sup> For knee disorders, guidelines recommended IFS for postoperative anterior cruciate ligament reconstruction, meniscectomy, and knee chondroplasty immediately postoperatively in the elderly.<sup>17</sup> This was a level C recommendation.

## American College of Physicians and the American Pain Society

In 2009, the clinical practice guidelines from the American College of Physicians and the American Pain Society concluded that there was insufficient evidence to recommend IFS for the treatment of low back pain.<sup>18</sup> An update of these guidelines by the American College of Physicians (2017) confirmed the 2009 findings that there was insufficient evidence to determine the effectiveness of IFS for the treatment of low back pain.<sup>19</sup>

## National Institute for Health and Care Excellence

In 2016, the National Institute for Health and Care Excellence published a guideline (NG59) on assessment and management of low back pain and sciatica in people aged 16 and over.<sup>3</sup> The guideline states, "Do not offer interferential therapy for managing low back pain with or without sciatica."

## U.S. Preventive Services Task Force Recommendations

Not applicable.

## Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

## REFERENCES

- Hussein HM, Alshammari RS, Al-Barak SS, et al. A Systematic Review and Meta-analysis Investigating the Pain-Relieving Effect of Interferential Current on Musculoskeletal Pain. *Am J Phys Med Rehabil.* Jul 01 2022; 101(7): 624-633. PMID 34469914
- Zeng C, Li H, Yang T, et al. Electrical stimulation for pain relief in knee osteoarthritis: systematic review and network meta-analysis. *Osteoarthritis Cartilage.* Feb 2015; 23(2): 189-202. PMID 25497083
- National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management [NG59]. 2016; <https://www.nice.org.uk/guidance/ng59>. Accessed May 31, 2023.
- Fuentes JP, Armijo Olivo S, Magee DJ, et al. Effectiveness of interferential current therapy in the management of musculoskeletal pain: a systematic review and meta-analysis. *Phys Ther.* Sep 2010; 90(9): 1219-38. PMID 20651012
- Kadı MR, Heppler S, Atamaz FC, et al. Is interferential current effective in the management of pain, range of motion, and edema following total knee arthroplasty surgery? A randomized double-blind controlled trial. *Clin Rehabil.* Jun 2019; 33(6): 1027-1034. PMID 30764635
- Alqualo-Costa R, Rampazo P, Thome GR, et al. Interferential current and photobiomodulation in knee osteoarthritis: A randomized, placebo-controlled, double-blind clinical trial. *Clin Rehabil.* Oct 2021; 35(10): 1413-1427. PMID 33896234
- Iacono R, Ramage L, Malakounides G. Current State of Neuromodulation for Constipation and Fecal Incontinence in Children: A Systematic Review. *Eur J Pediatr Surg.* Dec 2019; 29(6): 495-503. PMID 30650450
- Kajbafzadeh AM, Sharifi-Rad L, Nejat F, et al. Transcutaneous interferential electrical stimulation for management of neurogenic bowel dysfunction in children with myelomeningocele. *Int J Colorectal Dis.* Apr 2012; 27(4): 453-8. PMID 22065105
- Clarke MC, Chase JW, Gibb S, et al. Improvement of quality of life in children with slow transit constipation after treatment with transcutaneous electrical stimulation. *J Pediatr Surg.* Jun 2009; 44(6): 1268-72; discussion 1272. PMID 19524752
- Moore JS, Gibson PR, Burgell RE. Randomised clinical trial: transabdominal interferential electrical stimulation vs sham stimulation in women with functional constipation. *Aliment Pharmacol Ther.* Apr 2020; 51(8): 760-769. PMID 32128859
- Coban Ş, Akbal E, Kkl S, et al. Clinical trial: transcutaneous interferential electrical stimulation in individuals with irritable bowel syndrome - a prospective double-blind randomized study. *Digestion.* 2012; 86(2): 86-93. PMID 22846190
- Kkl S, Kkl G, Ozgl E, et al. Clinical trial: interferential electric stimulation in functional dyspepsia patients - a prospective randomized study. *Aliment Pharmacol Ther.* May 2010; 31(9): 961-8. PMID 20136803

13. Suh HR, Han HC, Cho HY. Immediate therapeutic effect of interferential current therapy on spasticity, balance, and gait function in chronic stroke patients: a randomized control trial. Clin Rehabil. Sep 2014; 28(9): 885-91. PMID 24607801
14. Eslamian F, Farhoudi M, Jahanjoo F, et al. Electrical interferential current stimulation versus electrical acupuncture in management of hemiplegic shoulder pain and disability following ischemic stroke-a randomized clinical trial. Arch Physiother. 2020; 10: 2. PMID 31938571
15. American College of Occupational and Environmental Medicine (ACOEM). Shoulder Disorders Guideline (2016). [https://www.dir.ca.gov/dwc/MTUS/ACOEM\\_Guidelines/Shoulder-Disorders-Guideline.pdf](https://www.dir.ca.gov/dwc/MTUS/ACOEM_Guidelines/Shoulder-Disorders-Guideline.pdf). Accessed May 31, 2023.
16. Hegmann KT, Travis R, Andersson GBJ, et al. Non-Invasive and Minimally Invasive Management of Low Back Disorders. J Occup Environ Med. Mar 2020; 62(3): e111-e138. PMID 31977923
17. American College of Occupational and Environmental Medicine (ACOEM). Knee Disorders. In: Hegmann KT, ed. Occupational medicine practice guidelines. Evaluation and management of common health problems and functional recovery in workers. 3rd ed. Elk Grove Village, IL: ACOEM; 2011:1-503.
18. Chou R, Atlas SJ, Stanos SP, et al. Nonsurgical interventional therapies for low back pain: a review of the evidence for an American Pain Society clinical practice guideline. Spine (Phila Pa 1976). May 01 2009; 34(10): 1078-93. PMID 19363456
19. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. Apr 04 2017; 166(7): 514-530. PMID 28192789

## POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
September 2011	New policy	
June 2012	Replace policy	Policy updated with literature search; references 6 and 7 added; other references re-numbered or removed. Policy statement changed to not medically necessary to use IFS for the treatment of pain
March 2013	Replace policy	Policy updated with literature search. References 5, 9-12 added; other references renumbered or removed. Policy changed to included not medically necessary for treatment of other conditions. Title changed to "Interferential Current Stimulation.,
March 2014	Replace policy	Policy updated with literature review; references 4 and 12 added; other references renumbered or removed. No change in policy statement.
March 2015	Replace policy	Policy updated with literature review. References 7, 12, and 14-16 added. No change in policy statement.
December 2017	Replace policy	Policy updated with literature review through July 21, 2017; no references added; references 18-20 updated. Policy statement corrected from "not medically necessary, to "investigational, due to FDA 510(k) clearance.
September 2018	Replace policy	Policy updated with literature review through April 9, 2018; reference 17 added. Policy statement unchanged.
September 2019	Replace policy	Policy updated with literature review through April 30, 2019, no references added. Policy statement unchanged.
September 2020	Replace policy	Policy updated with literature review through April 17, 2020; references added. Policy statement unchanged.
September 2021	Replace policy	Policy updated with literature review through May 3, 2021; references added. Policy statement unchanged.
September 2022	Replace policy	Policy updated with literature review through April 22, 2022; reference added. Policy statement unchanged.
September 2023	Replace policy	Policy updated with literature review through April 19, 2023; no references added. Policy statement unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.